AXON - Voyager's Parkinson's Gene Therapy Is Likely To Fail
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company focused on developing treatments for patients suffering from severe neurological diseases using an adeno-associated virus, or AAV, gene therapy approach, that either increases or decreases the production of a specific protein.
Pipeline
(source: 2017 annual report)
Voyager's pipeline consists of six programs for severe neurological indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis, or ALS; Huntington’s disease; Friedreich’s ataxia; tau-related diseases including Alzheimer’s disease, frontotemporal dementia, and progressive supranuclear palsy; and severe, chronic pain.
Given VY-AADC in the only